0000929638-23-001710.txt : 20230609
0000929638-23-001710.hdr.sgml : 20230609
20230609171037
ACCESSION NUMBER: 0000929638-23-001710
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230608
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hubbard John W
CENTRAL INDEX KEY: 0001622323
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36464
FILM NUMBER: 231006279
MAIL ADDRESS:
STREET 1: 101 POOR FARM ROAD 3RD FLOOR
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGILE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001261249
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 COLLEGE ROAD EAST
STREET 2: SUITE 310
CITY: PRINCETON
STATE: NJ
ZIP: 08540-6635
BUSINESS PHONE: 609-683-1880
MAIL ADDRESS:
STREET 1: 500 COLLEGE ROAD EAST
STREET 2: SUITE 310
CITY: PRINCETON
STATE: NJ
ZIP: 08540-6635
4
1
form4.xml
X0407
4
2023-06-08
0001261249
AGILE THERAPEUTICS INC
AGRX
0001622323
Hubbard John W
500 COLLEGE ROAD EAST, SUITE 310
PRINCETON
NJ
08540
true
false
Common Stock
2023-06-08
4
A
0
935
0
A
976
D
Employee Stock Option (Right to Buy)
3.58
2023-06-08
4
A
0
1065
0
A
2033-06-07
Common Stock
1065
1065
D
These shares represent restricted stock units that were granted on June 8, 2023, which will vest and be settled in common stock on June 8, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
On April 10, 2023 the Issuer completed a one-for-fifty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
This option was granted on June 8, 2023 and vests in full on June 8, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
/s/ Geoffrey P. Gilmore, Attorney-in-fact
2023-06-09